ChoiceSpine Launches Harrier ALIF System
ChoiceSpine launched HARRIER™, a PEEK-based anterior lumbar interbody fusion system. Feb 07, 2017
SpineGuard’s Dynamic Surgical Guidance Granted New US Patent
SpineGuard was granted a U.S. patent for Dynamic Surgical Guidance™ (DSG) technology addressing the application of bone quality measurement. Feb 07, 2017
Micro C Secures Seed Funding
Micro C secured US $0.7MM in seed funding. Proceeds will support 2Q17 milestones such as prototype build, testing, FDA submission and launch activities for its portable extremity imaging system. Feb 06, 2017
FlowerAdvantage: Efficiency and Savings Partnership for ASCs
Flower Orthopedics launched the FlowerAdvantage™ initiative, designed to reduce the costs to provide fracture repair in ambulatory surgery centers. Feb 06, 2017
Third FDA Clearance for Minuteman G3-R Implant
Spinal Simplicity received its third FDA 510(k) clearance for the Minuteman G3-R spinal implant. Feb 06, 2017
Vertebral Technologies Enters GPO Contract
Vertebral Technologies entered into a GPO contract to provide modular interbody fusion devices to member facilities of Resource Optimization & Innovation/ROi. Feb 06, 2017
Trice Medical Partners with Pacific Medical
Trice Medical entered into an agreement with Pacific Medical for multi-state distribution of the mi-eye 2™ in-office arthroscopic diagnostic tool in the U.S. Feb 03, 2017
SpineSource to Market Kisco’s L-Varlock Expandable Lumbar Cage
SpineSource entered into a long-term exclusive U.S. agreement to distribute Kisco International’s L-Varlock® Expandable Lumbar Cage for vertebral interbody fusion. Feb 03, 2017
Vexim Granted Patents in China and Japan
Vexim expanded its SpineJack® patent portfolio in Asia with the issuance of new patents in Japan and China. Further, the company is initiating biological and mechanical qualifying tests required to register its products by the China FDA. Feb 03, 2017
FDA Approves Expanded 26-week Efficacy Claim for Gel-One to Knee OA Pain
Zimmer Biomet announced FDA approval of an expanded 26-week efficacy claim for single-injection Gel-One® Cross-linked Hyaluronate viscosupplement for the treatment of knee pain associated with osteoarthritis. Feb 02, 2017
